Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468

Cell Proliferation

Volumn 45, Issue 3, 2012, Pages 199-206

  Saravani, R ^a   Karami Tehrani, F ^a   Hashemi, M ^b,c   Aghaei, M ^d   Edalat, R ^e  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; CYCLIC GMP; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; COLORIMETRY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84859857528     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2012.00819.x     Document Type: Article

References (33)

1. Rentero C, Monfort A, Puigdomenech P (2003) Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem. Biophys. Res. Commun. 301, 686-692.
2. Eigenthaler M, Lohmann SM, Walter U, Pilz RB (1999) Signal transduction by cGMP-Dependent protein kinases and their emerging roles in the regulation of cell adhesion And gene expression. Rev. Physiol. Biochem. Pharmacol. 135, 173-209.
3. Smolenski A, Burkhardt AM, Eigenthaler M, Butt E, Gambaryan S, Lohmann SM et al. (1998) Functional analysis of cGMP - dependent protein kinases I and II as media - Tors of NO/cGMP effects. Naunyn-Schmiedeberge Arch. Pharmacol. 358, 134-139.
4. Vaandrager AB, De Jonge HR (1996) Signalling by cGMP-dependent protein kinases. Mol. Cell. Biochem. 157, 23-30.
5. Loweth AC, Williams GT, Scarpello JH, Morgan NG (1997) Evidence for the involvement of cGMP and protein kinase G in nitric oxide-induced apoptosis in the pancreatic B-cell line, HIT-T15. FEBS Lett. 400, 285-288.
6. Shimojo T, Hiroe M, Ishiyama S, Ito H, Nishikawa T, Marumo F (1999) Nitric oxide induces apoptotic death of cardiomyocytes via a cyclic-GMP-dependent pathway. Exp. Cell Res. 247, 38-47.
7. Diederen RM, La Heij EC, Markerink-van Ittersum M, Kijlstra A, Hendrikse F, de Vente J (2007) Selective blockade of phosphodiesterase types 2, 5 and 9 results in cyclic 3'5' guanosine monophosphate accumulation in retinal pigment epithelium cells. Br. J. Ophthalmol. 91, 379-384.
8. Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE et al. (2011) The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-((3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydr o-2H-pyran-4-yl)-1, 5-dihydro-4H-pyrazolo[3, 4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 61, 665-676.
9. Wang P, Wu P, Egan RW, Billah MM (2003) Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene 314, 15-27.
10. Marko D, Romanakis K, Zankl H, Furstenberger G, Steinbauer B, Eisenbrand G (1998) Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts. Cell Biochem. Biophys. 28, 75-101.
11. Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F et al. (2010) Targeting cancer with phosphodiesterase inhibitors. Expert Opin. Investig. Drugs 19, 117-131.
12. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L et al. (2001) Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 61, 3961-3968.
13. Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y et al. (2010) Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev. Res. (Phila) 3, 1303-1313.
14. Francis SH, Blount MA, Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev. 91, 651-690.
15. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V et al. (2002) In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J. Exp. Med. 196, 1373-1380.
16. Chen TC, Wadsten P, Su S, Rawlinson N, Hofman FM, Hill CK et al. (2002) The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol. Ther. 1, 268-276.
17. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M (2005) Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol. 68, 1775-1781.
18. van der Staay FJ, Rutten K, Barfacker L, Devry J, Erb C, Heckroth H et al. (2008) The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 55, 908-918.
19. Aghaei M, Panjehpour M, Karami-Tehrani F, Salami S (2011) Molecular mechanisms of A3 Adenosine receptor-induced G1 cell cycle arrest and Apoptosis in androgen-dependent and independent prostate cancer cell line: involvement of intrinsic pathway. J. Cancer Res. Clin. Oncol. 137, 1511-1523.
20. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
21. Farrow KN, Groh BS, Schumacker PT, Lakshminrusimha S, Czech L, Gugino SF et al. (2008) Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ. Res. 102, 226-233.
22. Fallahian F, Karami-Tehrani F, Salami S, Aghaei M (2011) Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J. 278, 3360-3369.
23. Hashemi M, Karami-Tehrani F, Ghavami S, Maddika S, Los M (2005) Adenosine and deoxyadenosine induces apoptosis in oestrogen receptor-positive and -negative human breast cancer cells via the intrinsic pathway. Cell Prolif. 38, 269-285.
24. Ghavami S, Kerkhoff C, Los M, Hashemi M, Sorg C, Karami-Tehrani F (2004) Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions. J. Leukoc. Biol. 76, 169-175.
25. Hendrix M (2005) Selective inhibitors of cGMP phosphodiestrases as procognitive agents. BMC Pharmacol. 5, S5.
26. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 202, 419-443.
27. Zhu B, Vemavara L, Thompson WJ, Strada SJ (2005) Suppression of cyclic GMP-specific phosphodiestrase 5 promotes apoptosis and inhibits growth in HT 29 cell. J. Cell. Biochem. 94, 336-350.
28. Hirsh L, Dantes A, Suh BS, Yoshida Y, Hosokawa K, Tajima K et al. (2004) Phosphodiesterase inhibitors as anti-cancer drugs. Biochem. Pharmacol. 68, 981-988.
29. Marko D, Pahlke G, Merz KH, Eisenbrand G (2000) Cyclic 3', 5'-nucleotide phosphodiesterases: potential targets for anticancer therapy. Chem. Res. Toxicol. 13, 944-948.
30. Fraser M, Chan SL, Chan SS, Fiscus RR, Tsang BK (2006) Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 25, 2203-2212.
31. Tai CJ, Chang SJ, Chien LY, Leung PC, Tzeng CR (2005) Adenosine triphosphate induces activation of caspase-3 in apoptosis of human granulosa-luteal cells. Endocr. J. 52, 327-335.
32. Zhang YX, Yu SB, Ou-Yang JP, Xia D, Wang M, Li JR (2005) Effect of protein kinase C alpha, caspase-3, and survivin on apoptosis of oral cancer cells induced by staurosporine. Acta Pharmacol. Sin. 26, 1365-1372.
33. Janicke RU, Sprengart ML, Wati MR, Porter AG (1988) Caspase-3 required for DNA fragmentation, and morphological changes associated with apoptosis. J. Biol. Chem. 273, 9357-9360.